Medications for Melanoma

7 results

  • Imlygic

    (talimogene laherparepvec)
    Amgen Inc
    Usage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients with recurrence after surgery. It does not improve overall survival or affect visceral metastases.

  • Keytruda

    (pembrolizumab)
    Merck Sharp & Dohme LLC
    Usage: KEYTRUDA® is indicated for various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma, among others. It is utilized in different settings, such as first-line treatment, adjuvant therapy, and for those with advanced or refractory disease.

  • Mektovi

    (BINIMETINIB)
    Array BioPharma Inc.
    Usage: MEKTOVI is indicated for the treatment of patients with unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC), both with BRAF V600E or V600K mutations, in combination with encorafenib, as confirmed by an FDA-approved test.

  • Opdualag

    (nivolumab and relatlimab-rmbw)
    E.R. Squibb & Sons, L.L.C.
    Usage: OPDUALAG™ is indicated for the treatment of adult and pediatric patients aged 12 and older with unresectable or metastatic melanoma.

  • Proleukin (aldesleukin)

    (aldesleukin)
    Prometheus Laboratories Inc.
    Usage: Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma. Patient selection is crucial, emphasizing the need for screening and assessment of performance status to optimize response rates and minimize toxicity.

  • Tecentriq

    (atezolizumab)
    Genentech, Inc.
    Usage: TECENTRIQ is indicated for various cancers: as adjuvant treatment and first-line therapy for non-small cell lung cancer (NSCLC); for extensive-stage small cell lung cancer (ES-SCLC); for unresectable or metastatic hepatocellular carcinoma (HCC); and for melanoma with BRAF V600 mutation. It also treats unresectable alveolar soft part sarcoma.